Suppression of gain-of-function mutant p53 with metabolic inhibitors reduces tumor growth in vivo

6Citations
Citations of this article
25Readers
Mendeley users who have this article in their library.

Abstract

Mutation of p53 occasionally results in a gain of function, which promotes tumor growth. We asked whether destabilizing the gain-of-function protein would kill tumor cells. Downregulation of the gene reduced cell proliferation in p53-mutant cells, but not in p53-null cells, indicating that the former depended on the mutant protein for survival. Moreover, phenformin and 2-deoxyglucose suppressed cell growth and simultaneously destabilized mutant p53. The AMPK pathway, MAPK pathway, chaperone proteins and ubiquitination all contributed to this process. Interestingly, phenformin and 2-deoxyglucose also reduced tumor growth in syngeneic mice harboring the p53 mutation. Thus, destabilizing mutant p53 protein in order to kill cells exhibiting "oncogene addiction" could be a promising strategy for combatting p53 mutant tumors.

Cite

CITATION STYLE

APA

Jung, C. L., Mun, H., Jo, S. Y., Oh, J. H., Lee, C. H., Choi, E. K., … Suh, Y. A. (2016). Suppression of gain-of-function mutant p53 with metabolic inhibitors reduces tumor growth in vivo. Oncotarget, 7(47), 77664–77682. https://doi.org/10.18632/oncotarget.12758

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free